글로벌 키나제 억제제 시장 – 2029년까지의 산업 동향 및 예측

키나제 억제제 시장 분석 및 규모

키나제 억제제 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 역동적인 암 R&D 분야는 많은 유형의 암과 기타 질병에서 매개체로서 필수적인 역할을 하는 키나제에 대한 전문화를 개선할 수 있도록 허용하고 있습니다. 암 치료에 사용되는 항혈관신생 수용체 티로신 키나제 억제제에서 최신 발전이 이루어지고 있습니다. 여러 회사가 섬유증 및 기타 질병에 대한 약물 발견을 가속화하기 위해 분자 모델링에서 효능을 높이고 있습니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

 Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 키나제 억제제 시장의 성장률을 분석합니다. 글로벌 키나제 억제제 시장의 예상 CAGR은 언급된 예측 기간 동안 약 7.2%인 경향이 있습니다. 시장은 2021년에 561억 달러로 평가되었으며 2029년까지 978억 4천만 달러까지 성장할 것입니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

키나제 억제제 시장 범위 및 세분화

Market Definition

Kinase inhibitors are the drug class that restricts the action of kinases by adding a phosphate group to protein so that function of kinase gets disrupted. Kinases are involved in several cellular activities, including cell proliferation, differentiation, cell cycle, and cell apoptosis. Their inhibition can negatively impact a cell, causing it to die or fail to function properly. Most important types are therefore used to treat a diversity of diseases where this type of disruption is important to be involved, such as cancer, diabetes, and inflammation.

Global Kinase Inhibitors Market Dynamics

Drivers

• Technological Innovations

The kinase inhibitors market is projected to expand during the forecast period. Innovations such as artificial intelligence are transforming the market for kinase inhibitors. For instance, the U.S. biotechnology startup Insilico Medicine revealed its deep learning system, which can identify potential treatments for fibrosis with the help of DDR1 (Discoidin Domain Receptor 1) kinase inhibitors. Besides this, several healthcare companies are capitalizing on generative adversarial networks (GANs) to produce novel molecular structures with specified properties. Similarly, deep learning is letting companies with the rapid identification of potent DDR1 kinase inhibitors. Thus, all these advancements lead to the market growth.

• Increasing Prevalence of Cancer

Rise in the occurrence of cancer patients among the population is the primary cause of the growth of the global kinase inhibitors market. As per the Cancer Research UK data, about 17 million new cancer cases were reported globally in 2018 and almost 27.5 million new cancer cases are likely to be observed worldwide by 2040. Thus, this increasing prevalence of cancer is demanding more kinase inhibitors and which in return is boosting the market growth.

Opportunities

• Growing Adoption of Biochemistry

Novel assays and profiling techniques are serving companies to develop improved kinase inhibitors for drug development. The discovery of new kinase inhibitors is projected to improve biochemical, cellular, and in vivo assays that are assisting in offering new therapeutic targets. Companies in the kinase inhibitors market are growing R&D to gain expertise in cell signaling for the huge development of new drugs. Several companies are making more and more efforts to gain information on biochemical and biophysical assays to study the potency and selectivity of kinase inhibitors. Thus, these developments are creating huge efforts for the market expansion.

• Expanding Indications of kinase inhibitors

Increasing indications of existing and pipeline kinase inhibitors also create many opportunities for market growth. For instance, BCR-ABL TKIs, which were earlier approved for treating CML, are now indicated to treat acute lymphoblastic leukemia (ALL) and gastrointestinal tumors. Likewise, EGFR TKIs are approved for a collection of indications such as pancreatic cancer, breast cancer, and non-small cell lung cancer.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could limit the growth of the global kinase inhibitors market over a forecast period.

• High Cost

The R&D has higher costs and complex approval processes by respective governments, which restricts the market's growth significantly. Furthermore, the high development cost of drugs causes the higher market price of the drug post-approval. Therefore, the cost of the treatment has been limiting the market growth up to a certain level.

This kinase inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the kinase inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Kinase Inhibitors Market

COVID-19 has left a major global public health crisis which has impacted practically every business. Shift from healthcare infrastructure towards managing COVID-19 has led to drug launch withdrawals and delays in clinical trials.

In the post-pandemic era, the biotechnology and pharmaceutical industries are estimated to witness enormous future growth due to the demand for vaccine and treatment drugs for COVID-19. It has been witnessed that the non-receptor tyrosine kinase inhibitors result in the highest revenue share of the market in 2021 and are projected to lead the market in the post-COVID-19 period due to their high effectiveness in the treatment of autoimmune and inflammatory skin diseases such as rheumatoid arthritis.

Recent Developments

• In September 2020, Boehringer Ingelheim announced the final analysis from GioTag. This is a real-world retrospective, observational study which showed that Giotrif/Gilotrif followed by osimertinib witnessed median overall survival (OS) of 37.6 months in patients with EGFR mutation-positive Non-Small-Cell Lung Cancer (NSCLC).
• In February 2021, Novartis received the Breakthrough Therapy designation (BTD) grant by the U.S. FDA for asciminib to treat adult patients having Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), which was earlier treated with 2 or more tyrosine kinase inhibitors (TKIs).
• In November 2021, HUTCHMED and AstraZeneca started SACHI Phase III Trial of ORPATHYS and TAGRISSO combination in specific lung cancer patients in China after progression on EGFR inhibitor therapy.

Global Kinase Inhibitors Market Scope

The global kinase inhibitors market is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Tyrosin Kinase Inhibitors
• VEGFR
• PDGFR
• EGFR
• ALK
• HER2
• Mulikinase Inhibitors
• Cabozantinib
• Imatinib
•  Lenvatinib
• Regorafenib
• mTOR Kinase Inhibitors
• Sirolimus
• Everolimus
• Temsirolimus
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Kinase Inhibitors Market Regional Analysis/Insights

The global kinase inhibitors market is analysed and market size insights and trends are provided by type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global kinase inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

북미 지역은 암 유병률 증가와 암 환자를 위한 치료 옵션의 확대로 인해 예측 기간 동안 글로벌 키나제 억제제 시장이 긍정적인 성장을 보일 것으로 예상됩니다.

아시아 태평양 지역이 정부의 자금 지원과 인지도로 인해 시장을 지배하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 글로벌 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 글로벌 키나제 억제제 시장 점유율 분석

글로벌 키나제 억제제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 키나제 억제제 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 키나제 억제제 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 노바티스 AG(스위스)
• 엔도 인터내셔널 주식회사(아일랜드)
• Teva Pharmaceutical Industries Ltd(이스라엘)
• Glenmark Pharmaceuticals Ltd(인도)
• Cipla Inc(인도)
• Dr Reddy's Laboratories Ltd(인도)
• 애벗(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 파이저 주식회사(미국)
• 루팡(인도)
• 다케다제약 주식회사(일본)
• Akorn, Incorporated (미국)
• Torrent Pharmaceuticals Ltd. (인도)
• Amneal Pharmaceuticals LLC. (미국)
• 아스텔라스파마 주식회사(일본)
• 시에라 온콜로지(캐나다)

SKU-54370